Connetics (899160) Ich habs ja gesagt ! Heute wieder + 27,4% - 500 Beiträge pro Seite

[V.Mac]

Hi, Leute !

Auch mit Biotech-Nebenwerten, wenn man sie so bezeichnen kann, ist jede Menge Kohle zu machen.

Am 18.6.00 eröffnete ich den ersten Thread zu der Firma.

Siehe Thread: Connetics Corp - vom Pharma- zum Biotech-Unternehmen ?

Bis heute haben wir auf EURO-Basis, Kurs in Berlin + 82% gemacht.

Auf USD - Basis ( Schlußkurs heute ) siehts noch besser aus. Was einfach schade ist, ist die mangelnde Diskussionsbereitschaft hier über unbekannte Werte. Auch eine Hartcourt hat mal so angefanngen.
Für alle Interessierten : Schaut mal in den oben genannten Thread.

Auf der anderen Seite gilt wie immer: Wer nicht will der hat schon.

Schönen Abend noch.

Zur Vereinfachung noch mal den Chart von Connetics. Quelle: bigcharts.com



V.Mac

[V.Mac]

Gleich noch ne Bestätigung meiner Aussagen bezüglich Kursziel:

http://www.stockgroup.com/story.asp?mysection=sectors&mypage…

V.Mac

[Jean_II]

Was ist denn da mit den Umsätzen in Amerika los?
Die ziehen ja brutal an, gabs da irgendeine Meldung in den
letzten Tagen?
Sehe den Chart gerade zum ersten mal an, da wird ja gekauft, was das Zeug hält, ein Biotech, der auf ATH steht, nicht schlecht, was Du da ausgegraben hast!
Was machen die denn genau, stell doch mal paar Infos rein, oder gibts die schon, werde mal nachschaun!
Gruss Jean_II

[Jean_II]

So habs schon im anderen Thread gefunden, sieht sehr interessant aus, die Pharmasparte soll allein schon 16$ wert sein stand in der einen Analyse, das hört sich doch supergut an, schade bin leider wohl etwas zu spät dran, der Anstieg von 16 auf 24 in den letzten Tagen und die stark steigenden Umsätze, halten mich erstmal noch fern denke ich, aber um die 20 würde ich da schon gerne rein, vielleicht drückt ein "Oktobertief" die nochmal da hin!
Viel Spaß und Erfolg wünsche ich Euch mit Connetics!

[V.Mac]

sowas ! da ist doch wirklich ein Interessierter !

Tach erst mal.

Heute konsolidiert auch im allgemein schwachen Markt die Connetics mal. Ist aber bei der rasanten Entwicklung der letzten Tage nicht weiter verwunderlich.

Aktuell ca 23,8 USD

Aber bis Ende des Jahres gibts mit Sicherheit neue ATH´s zu bewundern.

V.Mac

[V.Mac]

Tja, und heute haben wir (zumindest in D ) die magische 30 er Grenze überschritten.

News gibts keine, aber das im anderen Thread zuerst genannte Kursziel ist fast erreicht, schneller als man denkt.

Jetzt stehen eben die 48 USD an.

Weiter so.

V.Mac

[puhvogel]

Boah, noch ein Rückschlag
http://biz.yahoo.com/prnews/001008/ca_conneti.html

Connetics Announces Pivotal Trial Results of Relaxin for
Scleroderma
-- Trial Did Not Reach Primary Endpoint; Relaxin Development Program in Other
Indications Continues --
PALO ALTO, Calif., Oct. 8 /PRNewswire/ -- Connetics Corporation (Nasdaq: CNCT - news) today announced that a
Phase III trial investigating recombinant human relaxin in the treatment of diffuse systemic sclerosis, also known as
scleroderma, did not meet its primary endpoint. Based on the preliminary results, Connetics will not file a BLA for relaxin
in the treatment of scleroderma. Connetics will continue its relaxin clinical development programs in vascular diseases
and infertility. [..]

Ganz schön viele Pleiten in letzter Zeit: Scotia Holdings, Cell Pathways, Gliatech und nun Connetics. Die Fundamentals für Biotech sind zur Zeit nicht so gut, wie das zur Zeit behauptet wird.
Leute seid vorsichtig in dies nun fallenden Messer in diesem schlechten Börsenumfeld zu fassen!! Vor einem Jahr standen die noch bei 4 $
Der Puhvogel

[gholzbauer]

Ross Taylor, super Leistung, alle Achtung!
Wenn ich das richtig sehe, hatte er bei Kurs 25$ ein Kursziel 24$ und die Aktie auf "buy". Jetzt bei 5 1/2$ hat er ein Kursziel 10$ und "hold". Hahaha...



RESEARCH ALERT-Connetics cut to hold
NEW YORK, Oct 9 (Reuters) - UBS Warburg said analyst Ross Taylor cut his rating on Connetics Corp. (NASDAQ: CNCT) to hold from buy on Monday after the biotechnology company dropped plans to seek approval of a skin disease drug.

-- company said on Sunday it had dropped plans to seek approval of its drug relaxin to treat the skin disease scleroderma after a pivotal trial failed to meet its primary goals.
-- in report, analyst cut price target to $10 from $24.

-- "We estimate the company has sufficient cash and securities to sustain its operations for several years."
-- shares closed on Friday at $25-1/2.

[puhvogel]

Meine Warnung kann ich ja glatt wieder aufheben. Ich kann mich an kein Biotech-Unternehmen erinnern, dass satte 80 % an einem Tag gefallen ist. Ist aber Ausdruck dafür , wie negativ die Stimmung bisher ist.
Pleite sind die ja nun auch nicht gerade(80 Millionen Cash), auch wenn mich die Restpipeline und die bisherigen Verkaufszahlen nicht auf den ersten Blick umhauen, wenn ich ehrlich bin
@gholzbauer: Mir ist es unerklärlich, wie solche Analysten gerade den Kurs von Biotechs maßgeblich bewegen können. Drückt aber auch die Hilflosigkeit vieler Anleger aus.
Der Puhvogel

[gholzbauer]

Ich habe gerade das CNCT-CEO-und-CFO-Interview auf Radiowallstreet.com angehört und bin angenehm überrascht. CNCT scheint bei 5$ ein guter Kauf zu sein. Habe jetzt keine Zeit, schreibe evtl. später kurze Zusammenfassung des Inhalts.

[gholzbauer]

Die bei Lehman sind genauso blöd.
vorher:Kurs über 25$, Kursziel 48$, Rating:outperform
nachher:Kurs 5$, Kursziel 14$, Rating:neutral
Können die nicht rechnen oder was?


UPDATE 1-Connetics stock plummets after drug fails trial
(adds details in paragraphs 2,3,4,6,7)

NEW YORK, Oct 9 (Reuters) - Shares of Connetics Corp. (NASDAQ: CNCT) tumbled nearly 80 percent Monday on news that the biotechnology company had dropped plans to seek approval of a drug to treat the disease scleroderma after a pivotal Phase III trial of the medication failed to meet its primary goals.

Connetics shares were down $20-7/32 to $5-9/16 in morning trade on the Nasdaq stock market, easily making Connetics the session`s biggest percentage loser. The stock`s 52-week range is $4-1/16 to $28-3/4.

Scleroderma is a degenerative disease in which there is scarring to the skin, joints and internal organs. Typical symptoms include thickening and swelling of the ends of the fingers. The cause of the disease is unknown.

The Phase III trial for the drug Relaxin involved 239 patients with stable, moderate and severe diffuse scleroderma of less than five years` duration. The disappointing results caused two brokerage houses to cut their ratings on Connetics shares before the stock market opened.

UBS Warburg analyst Ross Taylor cut his rating to "hold" from "buy" and lowered his price target on the stock to $10 from $24. Taylor said in a note that he was still confident Connetics has "sufficient cash and securities to sustain its operations for several years."

"On a positive note, the (Relaxin) trial did provide important additional data on the biological activity of the drug, and Connetics plants to continue its development program for Relaxin in other diseases like peripheral vascular disease, infertility, congestive heart failure and coronary artery disease," Taylor said.

Lehman Brothers cut its rating on Connetics to "neutral" from "outperform" and lowered its 12-month price target to $14 from $48. Lehman said the price target was "based solely on the value of the (company`s) dermatology business," which it said is on target with an estimated $28.4 million in revenues in 2001 and growth rate of 30 percent.

On Sunday, Connetics Chief Financial Officer John Higgins characterized the Relaxin trial as a "bump in the road" that could occur in any drug`s development. He said the trial had produced a lot of positive data that could lead to Relaxin`s being tested for treating other diseases.

"Certainly, it`s a disappointment," Higgins told Reuters. "(But) the hurdle for success was pretty high in this trial ... and now we have so much data on how this drug might work in other diseases."

He said other areas for future development of Relaxin could include cardiovascular illnesses and infertility.

Connetics said detailed results of the trial would be presented on Oct. 24 at the Relaxin 2000 Conference in Broome, Australia.

[gholzbauer]

Interview auf Radiowallstreet.com
Relaxin=natürlich vorkommendes Schwangerschaftshormon;
Daten u.a. aus den Sklerodermitis-Phase-III-Tests zeigen positive Effekte auf Herz-Kreislauf-Krankheiten(cardiovascular diseases), Fruchtbarkeit (fertility) und Nierenkrankheiten (renal diseases), noch vor Ende dieses Jahres sollen für (proliferal?) arterial disease, fertility und congestive heart failure jeweils Phase-II-Wirksamkeits(efficiency)-Tests begonnen werden, deren Ergebnisse ein Jahr später vorliegen sollten.
Die entsprechenden Märkte sind wesentlich größer als der Skleroderma-Markt.
Cash beträgt 80 Mio.$, burn rate jährlich 15 Mio.$ inkl. der genannten neu geplanten Phase-II-Tests.
2 Produkte bereits auf dem Markt, 3. folgt innerhalb der nächsten Wochen. (s. auch Text oben: 28,4 Mio.$ Umsatz in 2001 mit 30% Wachstum erwartet) D.h. diese Produkte rechtfertigen bereits die jetzige Marktkap., dazu noch 2,7$/Aktie Cash; neben den neuen Relaxin-Indikationen will CNCT nächstes Jahr noch 2 weitere Dermatologie-Produkte in Phase III haben.

Habe schon Kaufauftrag gegeben. Hoffentlich hat 5,25$ vorhin noch geklappt, dürfte knapp gewesen sein.

Grüße,
gholzbauer

[gholzbauer]

Ausführung zu 5,16$!!! Weltklasse (erst mal)!

[V.Mac]

Ist schon komisch !

Monatelang unterhalte ich mich fast nur mit mir selbst und heute, wenns mal richtig zur Sache geht, sind dann noch ein paar Interessierte an Board. Wahrscheinlich sind wir auch die einzigen Leser, die den Thread bisher rund 250 mal gelesen haben.

Auf jeden Fall habe ich heute gedacht,ich kann meinen Augen nicht trauen. 80% wegen einer nicht erfolgreichen Testphase 3 sind wohl doch etwas überspitzt. Ich dachte zuerst, ich hätte in letzter Zeit nicht sorgfältig alle Artikel über CNCT gelesen und mir wäre ein 1:5 Split entgangen.

War aber nicht so.

Im Gegenzug kann man natürlich jetzt sagen: 1. Versuch war nix, aber die Ergebnisse bisher werden ja nicht einfach in den Müll geworfen. Jetzt spielt doch wieder die Fantasie mit rein:

Was ist in 12 Monaten, wenn.........?

Alerdings muß ich sagen, ich hatte das Glück, diesmal zum Ausstieg die richtige Zeit gefunden zu haben.

PS: Posting von mir vom 29.9.2000 hier : Wir werden bis Jahresende noch ATH´s bewundern.
Das heißt vorerst: Wir werden bis Jahresende noch ATL´s bewundern (All-time-low) Kleins Spässle !

V.Mac

PPS Leid tun mir nur die armen Schweine, die heute früh noch in Berlin und München zu über 20 € gekauft haben. Scheisse, wenn die Nachrichten nicht schnell genug über den grossen Teich kommen.

[gholzbauer]

Ich halte die jetzigen Kurse für eine gute Einstiegsgelegenheit. Falls es noch tiefer gehen sollte (4$ z.B.), werde ich nachlegen.
Heute und die nächsten Tage werden die day traders noch ordentlich für Bewegung sorgen, deshalb wär ein Abstauberlimit vielleicht nicht verkehrt.

[V.Mac]

@ gh

eine gigabell meldet konkurs/zahlungunfähigkeit an und die aktie verliert nur 50 % und noch mal 40 % bei Konkurs ! Daytrader pushen wieder bis auf das 6fache der Tiefstkurse um dann zwei tage später wieder am ATL zu stehen.

Connetics arbeitet nach wie vor profitabel, wenn auch die Ergebnisprognosen deutlich zurückgeschraubt werden müssen. Aber immer noch mit Gewinn!!!!!!!!!!!!!!!!! Und noch Cash für 2,5 Jahre !!!!!!!!!!

Der Kurs verliert 80 % !!!!!!!!! Nicht zu glauben.

Deshalb gebe ich dir recht. Auch ich werde, da ich die facts nun kenne, bald wieder einsteigen. Allerdings will ich die kurzfristige Marktentwicklung noch abwarten. Aber unter 5 € ...?

Es kann nur aufwärts gehen.

V.Mac

[gholzbauer]

SmallCapsOnline reiterates "buy" recommendation

http://www.smallcapsonline.com/index.php3?category=research&…

[gholzbauer]

Connetics` CEO Responds to Market Reaction During Live Interview
Full Interview Available at www.connetics.com
PALO ALTO, Calif., Oct 10, 2000 /PRNewswire via COMTEX/ -- Connetics Corporation (Nasdaq: CNCT chart, msgs) responded to the stock market`s reaction to an announcement issued yesterday that its Phase III trial investigating recombinant human relaxin in the treatment of diffuse systemic sclerosis, also known as scleroderma, did not meet its primary endpoint. During a live interview with CNBC, Thomas Wiggans, chief executive officer, was asked if the stock sell-off was too harsh of a reaction. He responded that he believed recent movement in the stock was, "in anticipation of the scleroderma results. I think the inherent value of the company is substantially more than it is right now."

When asked to comment on the company`s most promising product in the pipeline, Wiggans said, "Despite the setback in scleroderma, I think relaxin is still an enormously promising drug. We saw profound effects in renal function in the trial, we saw profound effects in cardiovascular function, and we saw profound effects in endometrial development." Wiggans also commented that these data support the other relaxin development programs that Connetics has had ongoing for up to a year and that the company is preparing to start clinical trials in congestive heart failure, peripheral arterial disease and infertility. He made the point that the most severe form of scleroderma affects about 100,000 people in the U.S. and congestive heart failure affects about five million.

Connetics currently markets two dermatology products and intends to launch a new product this quarter. The company expects to burn less than $15 million for the year and has more than $80 million in cash and marketable securities.

A transcript of the entire interview can be found on Connetics` Web site at www.connetics.com

Clinical Development Program for Relaxin

Relaxin is a naturally occurring hormone with several distinct biological activities including vasodilation, angiogenesis and inhibition of fibrosis. The hormone is thought to be responsible for many cardiovascular changes that occur during pregnancy, including increased blood flow, which is due to an increase in the number of vessels (angiogenesis) and an expansion in the diameter of vessels (dilation). The angiogenic effects are mediated by an upregulation of bFGF and VEGF by relaxin, and the vasodilatory effects are thought to be mediated by inhibiting the constrictive effects of angiotensin and endothelin.

Based on these discrete biological properties, Connetics has initiated development programs to expand on relaxin as a platform therapeutic treatment. The company has ongoing clinical programs in cardiovascular and peripheral vascular disease, as well as infertility.

[puhvogel]

Gleich im voraus: Die Aktie ist nicht teuer oder so etwas
Doch für den Begriff "Schnäppchen" fehlt mir da noch das Besondere.
a) Zu den Ergebnissen: Ich habe mal im letzten Quartalsbericht nachgeschaut
http://biz.yahoo.com/e/l/c/cnct.html
Die eigentlichen Verkaufszahlen für ihre Medikamente sind dem letzten Quartal sogar rückläufig (6Monatszahlen sind nicht vergleichbar, da der Luxiq-Verkauf erst im April 99 gestartet wurde. Bei Ridaura prophezeit CNCT : "Although Ridaura sales increased quarter over quarter, we believe that Ridaura will experience decreased sales for the remainder of 2000 due to competition from new and existing products." Also Verkaufszahlen wohl auch bald rückläufig.
Der Anstieg der Gesamteinnahmen stammen aus einem Einmalverkauf der Rechte an einem dritten Medikament an Intermune.
Als Positivum bleibt noch das neue Mittel OLUX, über dessen Verkaufserfolgchancen wir uns vermutlich noch keine Gedanken gemacht haben.
Wenn man das Unternehmen rein statisch fundametal betrachtet, dann ist eher eine Biochem mit ihrer zur Zeit ebenfalls noch langweiligen Pipeline ein Kauf.

b) zu den 80%: Der Kurs ist im Vorfeld der Ergebnsveröffentlichung stark angestiegen. Das sind mal wieder so Leute, die den Hals nicht vollkriegen und unbedingt volle Kanne Risiko fahren wollen, und den Kurs innerhalb kurzer Zeit beinahe verdoppelten. Sorry aber als Basis würde ich lieber 17 $ sehen.

c) Dieser Wert steckt meinesachtens in der Phantasiefalle. Bis wieder neue kursbewegende Meldungen anstehen , gehen so 1,5 Jahre ins Land: Erst wenn Phase 2 Ergebnisse veröffentlicht werden, kann man überhaupt feststellen ob die neuen Produkte überhaupt tendenziell wirken. Bisher weiss man nur, dass Relaxin keine großen Nebenwirkungen hat (ist ja immerhin schon was). Von den Phase3 Trials will ich ja gar nicht reden
Die Gefahr ist groß, dss sich die Aktionäre bald langweilen, und Langeweile ist schlecht für die Kurse von Biotechs.

d) Der Vergleich mit Cell Pathways erscheint mir nicht so probat, da bei CNCT die short ratio im Vorfeld des Kurssturzes nicht so riesig war.

e) Ich will Euch nicht vom Kauf abraten. Der Chart von PGNX widerlegt meine obige Thesen, was mich zugegebenermaßen sehr wundert. Ich wollte nur Meinung darlegen und Euch animieren, euch tiefer in das Umfeld der Firma einzuarbeiten als bisher.

Viel Glück
Der Puhvogel

[V.Mac]

kritische worte, begründet !!
Danke !

V.Mac

[gholzbauer]

Dennoch habe ich die besten Geschäfte gemacht, indem ich Werte, die zu dem Zeitpunkt keiner haben wollte, billigst eingesammelt habe. Wenn bei CNCT die Phantasie zurückkehrt, wird man bereits weit höhere Kurse bezahlen müssen, um noch einzusteigen. Ich habe bereits ein weiteres Abstauberlimit bei 4$ gesetzt.

[gholzbauer]

Connetics Reports Third Quarter Financial Results
PALO ALTO, Calif., Oct 23, 2000 /PRNewswire via COMTEX/ -- Connetics Corporation (Nasdaq: CNCT chart, msgs) today announced financial results for the third quarter ended September 30, 2000. Total revenues for the third quarter were $7.4 million as compared to $6.2 million in the same period last year. The increase in 2000 third quarter revenues represents increased product revenue from Luxiq(TM) (betamethasone valerate) Foam, 0.12%, higher than expected sales of Ridaura(R) and increased partnering revenue. Revenues for the first nine months of 2000 totaled $31.1 million, representing an increase of 52% over the same period in 1999.

Third quarter product sales of Luxiq increased approximately 109% to $2.9 million over last year`s third quarter sales of $1.4 million. Third quarter Ridaura sales were $2.8 million versus $2.0 million for the same period last year. Excluding sales from Actimmune(R), which was divested in June 2000, the 2000 year-to-date product sales increased by 59% over the same period last year.

Net loss was $5.3 million or ($0.18) per basic share for the quarter and $4.3 million or ($0.15) per basic share for the first nine months of 2000, as compared to a net loss of $8.0 million or ($0.37) per basic share for the third quarter 1999 and $18.7 million or ($0.88) per basic share for the first nine months of 1999.

At the close of the third quarter, Connetics had approximately $95.6 million in cash and marketable securities.

"We are pleased with the strong financial performance of the company this quarter and the continuing growth in prescriptions of our core brand, Luxiq," said Thomas G. Wiggans. "With Luxiq sales and the pending launch of our newest product, OLUX(TM), we expect to see continued revenue growth and cash flows from our commercial business. We recently announced results from our scleroderma trial with relaxin, and unfortunately we will not pursue a BLA filing for relaxin in scleroderma. However, based upon relaxin`s activity in cardiovascular parameters in the study, we remain committed to and excited about advancing relaxin development."

Relaxin Program

After the close of the quarter, Connetics announced that a Phase III trial investigating recombinant human relaxin in the treatment of diffuse systemic sclerosis, also known as scleroderma, did not meet its primary endpoint. Based on the preliminary results, Connetics will not file a BLA for relaxin in the treatment of scleroderma. Connetics will continue its relaxin clinical development programs in vascular diseases and infertility. Based on the scleroderma trial outcome, Celltech Group PLC and Suntory LTD have each notified Connetics that they will discontinue their collaborations with Connetics for the development of relaxin in Europe and Japan, respectively. All rights to relaxin under these agreements for Europe and Japan will revert to Connetics. Connetics is in discussions with both companies about how to wind down the relationships.

Recently, Connetics entered into an agreement with ALZA Corporation (NYSE: AZA chart, msgs) to develop an advanced drug delivery system for relaxin. The development work will focus on applying ALZA`s implantable drug delivery technology, or DUROS(R) system, to expand delivery options for relaxin. The current delivery system for Connetics` relaxin formulation involves the use of an external infusion pump.

Relaxin is a naturally occurring hormone with several distinct biological activities including vasodilation, angiogenesis and inhibition of fibrosis. The hormone is thought to be responsible for many cardiovascular changes that occur during pregnancy, including increased blood flow, which is due to an increase in the number of vessels (angiogenesis) and an expansion in the diameter of vessels (dilation). The angiogenic effects are mediated by an upregulation of bFGF and VEGF by relaxin, and the vasodilatory effects are thought to be mediated by inhibiting the constrictive effects of angiotensin and endothelin.

Based on these discrete biological properties, Connetics has initiated development programs to expand on relaxin as a platform therapeutic treatment. The company has ongoing clinical programs in cardiovascular and peripheral vascular disease, as well as infertility. Connetics will present a variety of relaxin data, including the results from the pivotal scleroderma trial, during the week of October 23 at the Relaxin 2000 Conference in Broome, Australia, which is being sponsored by the Howard Florey Institute at the University of Melbourne.

Connetics will hold a live Web cast/teleconference call to review the third quarter results on Monday, October 23, 2000 at 1:15 p.m. PDT/ 4:15 p.m. EDT. To participate, domestic callers should call 1-888-863-1556 and international callers should call 1-212-271-4814. Participants may also join the call over the Internet at www.connetics.com under the Investor Relations Page. If unable to participate on the live conference call, a replay will be available on Connetics` Web site at www.connetics.com from 4:00 p.m. PDT/ 7:00 p.m. EDT, October 23 through November 30. You may also hear the call by calling the replay number 1-800-633-8284 in the U.S., 1-858-812-6440 internationally, and entering pass code #16719314.

About Connetics

Connetics Corporation, headquartered in Palo Alto, California, is a biopharmaceutical company focused on the development of recombinant human relaxin for multiple indications and on the development and commercialization of novel therapeutics for the dermatology market. For more information about Connetics and its products, please visit Connetics` Web Site at www.connetics.com, or send e-mail to [e-mail].

This news release contains forward-looking statements and predictions about our expectation of continued revenue growth and cash flows from our commercial business, our continued relaxin clinical development programs in vascular diseases and infertility, and the development work with ALZA. These statements represent our judgment as of this date and are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed. Potential risks and uncertainties include, without limitation, continued demand for the our commercial products and future revenue trends, risks associated with new product development, risks inherent in continued clinical development programs, risks in managing expenses and risks that the value of our marketable securities may be affected by fluctuations in the stock market. These and other factors are discussed in more depth in Connetics` Form 10-K dated March 2, 2000, the Form S-3 filed July 10, 2000 and in the Company`s other filings with the SEC. These documents contain and identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.


CONNETICS CORPORATION
Condensed Statements of Operations
(In thousands, except per share amounts)
(Unaudited)

Three Months Ended Nine Months Ended
September 30, September 30,
2000 1999 2000 1999
Revenues:
Product $5,657 $4,773 $15,117 $11,656
License 1,735 1,400 10,810 8,779
Sale of Actimmune
revenue rights -- -- 5,218 --
Total Revenues 7,392 6,173 31,145 20,435
Operating expenses:
Cost of product sales 719 1,628 2,979 4,279
License amortization -- 1,680 -- 5,040
Research and development 5,828 5,783 15,956 14,363
Selling, general
and administrative 6,765 5,032 18,330 15,533
Total operating
expenses 13,312 14,123 37,265 39,215
Interest and other income 663 193 2,013 833
Interest expense (38) (225) (207) (749)

Net loss $(5,295) $(7,982) $(4,314) $(18,696)

Basic net loss per share $(0.18) $(0.37) $(0.15) $(0.88)

Shares used to calculate
basic net loss per share 29,507 21,588 28,032 21,353


Condensed Balance Sheets
(In thousands)

September 30, December 31,
2000 1999
(Unaudited)
Assets
Assets:
Cash and short-term investments $38,621 $26,299
Accounts receivable
and other current assets 2,327 2,425
Property and equipment, net 1,577 1,505
Marketable securities and other assets 57,355 181

Total assets $99,880 $30,410

Liabilities and Stockholders` Equity
Liabilities and stockholders` equity:
Current liabilities $9,315 $15,323
Other liabilities -- 799
Stockholders` equity 90,565 14,288

Total liabilities and
stockholders` equity $99,880 $30,410



Source: Connetics Corporation

[gholzbauer]

Zum Chart weiter oben: wie ist denn das mit dieser Theorie, daß "gaps" gefüllt werden müssen? Da haben wir noch einiges vor, oder?

[V.Mac]

@gholz..
ist aber wirklich der erste chart, der nicht in kompletten linien verläuft. Geht wahrscheinlich nicht soweit senkrecht nach unten, die darstellung !!

V.Mac

PS: Beim Kursanstieg wird eine vollständige Linie zu bewundern sein.

[gholzbauer]

Newly Published Preclinical Study Demonstrates Relaxin Selectively Stimulates VEGF and bFGF at Ischemic Sites
PALO ALTO, Calif., Oct 31, 2000 /PRNewswire via COMTEX/ -- Connetics Corporation (Nasdaq: CNCT chart, msgs) today announced the publication of preclinical study results assessing the ability of recombinant human relaxin to selectively induce angiogenesis, the growth of new blood vessels. The results, published in the September-October 2000 issue of Wound Repair and Regeneration, titled "Relaxin Induces Vascular Endothelial Growth Factor Expression And Angiogenesis Selectively At Wound Sites," suggest that relaxin may be useful in the treatment of ischemic conditions by stimulating angiogenesis through the induction of both vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) at ischemic sites.

"The publication of this research provides further evidence supporting relaxin`s selective pro-angiogenic properties," said Krisztina Zsebo, Ph.D., Executive Vice President, Research and Product Development. "VEGF and bFGF play a major role in the regulation of endothelial cell proliferation and angiogenesis, which are the key growth factors in vascular diseases. The profile demonstrated in these animal models and in other relaxin studies presented recently at the Third International Conference for Relaxin that took place last week, support our ongoing clinical development plans studying relaxin for peripheral arterial disease, coronary artery disease and infertility."

In the study, relaxin`s angiogenic effects on wound repair were studied in rodent models. To assess these effects, wounds were studied in normal and ischemic (oxygen deprived) tissue. Results showed relaxin induced significantly more blood vessel growth at ischemic sites as compared to animals treated with vehicle alone. Relaxin administration upregulated both VEGF and bFGF production following administration of drug. Significantly, relaxin was administered systemically but did not cause an increase in VEGF or bFGF in non-wound cells. This selective action may confer a significant advantage over administration of VEGF or bFGF directly, which may cause angiogenesis in a non-specific fashion. Because relaxin`s pro-angiogenic effects are observed after systemic administration, the need for local drug delivery is obviated.

Clinical Development Program for Relaxin

Relaxin is a naturally occurring hormone with a distinct spectrum of biological activities including the promotion of vasodilation, angiogenesis and inhibition of fibrosis. Based on these discrete biological properties, Connetics has initiated development programs to expand on relaxin as a platform therapeutic. The company has ongoing clinical programs in cardiovascular and peripheral vascular disease, as well as infertility.

[gholzbauer]

Connetics Announces the Availability of OLUX(TM) Foam and Product Marketing Exclusivity
Company`s Second Dermatology Product With Patient Preferred Novel Foam-Delivery Technology; FDA Grants Three Year Marketing Exclusivity For Product
PALO ALTO, Calif., Nov 6, 2000 /PRNewswire via COMTEX/ -- Connetics Corporation (Nasdaq: CNCT chart, msgs) today announced the availability of its super-high-potency corticosteroid, OLUX(TM) (clobetasol propionate) Foam, 0.05%. OLUX is a novel foam formulation for the short-term, topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive scalp dermatoses. In addition, Connetics announced today that it has received FDA-granted market exclusivity and patent protection on the product. Connetics received approval to market OLUX Foam in May 2000 and will begin shipping the product today.

The active ingredient in OLUX Foam, clobetasol propionate, is a super-high-potency corticosteroid. OLUX Foam delivers clobetasol propionate to affected areas through a novel foam modality. The foam vehicle is easier to apply, less messy and cosmetically more acceptable than many dermatological lotions, creams and ointments currently on the market. A market research study has shown that 80% of patients prefer the foam vehicle. High levels of patient acceptance for the foam vehicle have been cited by a leading dermatologist as a factor that may lead to increased patient compliance.

The FDA has granted marketing exclusivity to Connetics for foam-based products incorporating clobetasol propionate for three years. In addition, a U.S. patent was recently issued that covers the delivery technology that is the basis for OLUX as well as Connetics` other proprietary product, Luxiq(R). U.S. Patent 6,126,920 is licensed exclusively to Connetics pursuant to its license agreement with Soltec Research Pty Ltd. and covers methods of treating various skin diseases, and in particular, scalp psoriasis, using a foam pharmaceutical composition comprising a corticosteroid active substance, a propellant and a buffering agent.

"The introduction of OLUX Foam has the potential to significantly impact the way dermatoses are treated, offering dermatologists a patient-preferred, convenient and effective option," said Thomas G. Wiggans, Connetics Chief Executive Officer. "OLUX Foam is our second dermatology product. It represents a critical step in growing our dermatology franchise. The introduction of OLUX Foam demonstrates our product development capabilities and strategically complements Luxiq(R) Foam by offering dermatologists both a mid-potency and a super-high-potency steroid in our novel delivery modality. With this opportunity, we now offer two novel products to compete in the $600 million mid- and super-high-potency topical steroid market."

"OLUX Foam represents a significant revenue opportunity for Connetics," said Greg Vontz, Chief Commercial Officer. "The marketing exclusivity granted by the Food and Drug Administration will allow us to take full advantage of the opportunity to compete in the super-high-potency topical steroid market with this novel product."

In a Phase III, double-blind, active- and placebo-controlled trial of adult patients with moderate to severe scalp psoriasis, investigators` global assessments showed 74% of OLUX Foam-treated patients had complete (100%) or almost complete clearance (90% to 100%) of disease after 14 days compared with 63% treated with a clobetasol propionate solution. The trial also showed OLUX Foam was safe and well-tolerated. Connetics is also investigating OLUX Foam as a potential treatment for dermatoses in other areas of the body besides the scalp. Please visit http://www.olux.com for full OLUX Foam prescribing and safety information.

In March 1999, Connetics launched Luxiq(R) (betamethasone valerate) Foam, 0.12%, a mid-potency topical corticosteroid for the treatment of corticosteroid-responsive scalp dermatoses.

Several million Americans suffer from scalp dermatoses, which can flare up unpredictably and be a frequent source of physical irritation and embarrassment. Scalp dermatoses include conditions such as eczema, a superficial inflammation that causes itching and scaling, and seborrheic dermatitis, which commonly appears as itching, redness and scaling. One of the most common conditions is psoriasis, marked by redness and scaling, itching and irritation. According to the National Psoriasis Foundation, scalp psoriasis affects more than 3.2 million Americans.

[gholzbauer]

http://www.smallcapsonline.com./index.php3?category=research…

[V.Mac]

also der link ist nicht schlecht bzw. der dargestellte inhalt !

Ich denke, CNCT hat seinen Boden bei rund 6 USD gefunden, auch nicht schlecht, wenn mann bedenkt, daß in der ertsten Verkaufspanik der Kurs bis 4,80 USD gefallen ist.

Langfristig denke ich, das man ruhig wieder auf zweistellige Kurse hoffen kann.

V.Mac

[gholzbauer]

INTERMUNE SHAREHOLDER FILES FORM 144, TO SELL SHARES
WASHINGTON, DC, Nov. 15, 2000 (States via COMTEX) -- Connetics Corp., shareholder, Intermune Pharmaceuticals in Burlington, Calif., reported on Nov. 8, 2000, the proposed sale of 100,000 shares on Nov. 6, 2000, for $4,700,000 through Lehman Brothers Inc.

[gholzbauer]

CNCT sells 900,000 shares of ITMN - owns 149,445
Thursday November 16, 8:02 am Eastern Time
Press Release
SOURCE: Connetics Corporation
Connetics Generates $42.2 Million Through the Sale of InterMune Shares
PALO ALTO, Calif., Nov. 16 /PRNewswire/ -- Connetics Corporation (Nasdaq: CNCT - news) announced today that it has sold 900,000 shares of its holdings in InterMune Pharmaceuticals, Inc. (Nasdaq: ITMN - news). The sales, which have taken place over the last three weeks, have raised net proceeds for Connetics of approximately $42.2 million. Subsequently, Connetics owns 149,445 shares of InterMune. Connetics` holdings in InterMune are the result of spinning out the company in April 1998. Including cash balances as of September 30, 2000, Connetics has approximately $80 million in cash and cash equivalents.

``We have more than doubled our cash position and are able to invest in the growth of our business without the need for additional financings,`` said Thomas G. Wiggans, President and Chief Executive Officer. ``We are committed to our business strategy focused on revenue growth and late-stage product development. With our financial position and our commercialized products, including the recent launch of OLUX(TM), we believe we have a strong platform to build upon. We look forward to initiating clinical trials with new dermatology products and with relaxin in 2001.``

[gholzbauer]

Schon lange nichts mehr geschrieben worden hier!
CNCT ist in ganz guter Verfassung, heute haben wir mit 6.50$ wohl ein neues post-Absturz-Hoch.
Ich glaube, für 2001 dürfen wir optimistisch sein, 10 $ könnten IMO im Jahresverlauf schon drin sein.
Leider habe ich im Dezember bei 4$ nicht mehr nachgelegt, aber ich habe jetzt immerhin einen Durchschnittskaufkurs von gut 4.5$.
Wer ist noch dabei?
V.Mac?

[Braini]

bin auch dabei... aber nach dem steielen anstieg der letzten tage wird wohl erstmal konsolidieurng angesagtsein.

[gholzbauer]

Wednesday February 14, 11:07 am Eastern Time
Press Release
SmallCaps Online Announces Investment Opinion: SCO Group Reiterates Buy Recommendation On Connetics Corporation
Visit SmallCaps Online`s Web Site at www.SCOGroup.com for Detailed Report
NEW YORK--(BUSINESS WIRE)--Feb. 14, 2001-- SCO Group announced today that it has issued an update on Connetics Corporation. (NASDAQ: CNCT - news) and reiterated its BUY recommendation. The full text of the report can be accessed at SCOGroup`s web site, at www.SCOGroup.com

[Busmann]

...immerhin hat die investor realtions mappe ne nettes design :Q

[V.Mac]

Tja, hallo!!

Habe mich schon lange nicht gemeldet.

Auf die Frage weiter oben: nein, bin zum Zeitpunkt nicht wieder dabei. Gab bisher auch keine zufriedenstellende Entwicklung. Ging in einer recht schmalen Range seit Oktober seitwärts. Gut, ich weiß, zwischen Tief und dem folgenden Hoch wären auch fast 100 % möglich gewesen.

Aber um in Deutschland damit zu traden, ist einfach viel zu wenig Umsatz.

Auf jeden Fall gabs in den letzten Monaten reichlich Meldungen. Im Detail zu finden unter Bigcharts.com.

Connetics Corporation Announces First Quarter Conference Call/Webcast - PRNewswire 2:01 PM
Monday, April 23, 2001

Connetics Completes Acquisition of Soltec Research Pty Ltd - PRNewswire 7:01 AM
Friday, April 20, 2001

Faulding completes sale of Soltec Research - BusinessWire 9:05 AM
Wednesday, March 21, 2001

Connetics Corporation - Soltec Acquisition Conference Call - PRNewswire 7:00 AM

Connetics Announces Expansion of Dermatology Field Sales Organization - PRNewswire 7:00 AM
Tuesday, March 20, 2001

Faulding Divests Soltec Research - BusinessWire 9:30 PM
Connetics Agrees to Acquire Soltec Research Pty Ltd - PRNewswire 9:00 PM
Friday, February 23, 2001

Connetics Names New Senior Vice President Clinical Research - PRNewswire 4:30 PM
Connetics Names Greg Vontz Chief Operating Officer - PRNewswire 7:00 AM
Wednesday, February 14, 2001

SmallCaps Online Announces Investment Opinion: SCO Group Reiterates Buy Recommendation On Connetics Corporation - BusinessWire

Na und da muß ich mich erst mal wieder einlesen, vorallem in die Zahlen die bald kommen sollen.

Aber ich halte es wieder für einen interessanten Wert, allerdings will ich erst mal die Q 1 Zahlen abwarten.

V.Mac

[gholzbauer]

Hallo V.Mac,
hallo alle,

zur Erinnerung:

Connetics Earnings Conference Call (Q1 2001)
Scheduled to start Wed, May 2, 2001, 4:15 pm Eastern

Das bedeutet vermutlich auch, daß die Zahlen erst nachbörslich während des CC bekanntgegeben werden.

Kursausschläge dürfen erwartet werden.

MfG

[V.Mac]

Zahlen :



Connetics Reports First Quarter Financial Results

Strong Product Revenue Growth and Increased Gross Margins

PALO ALTO, Calif., May 2 /PRNewswire/ --
Connetics Corporation (Nasdaq: CNCT) today announced financial results for the
quarter ended March 31, 2001. The first quarter results include record
product revenues of $7.7 million as compared to $5.7 million in the first
quarter of 2000. Product gross margin increased to 85.6% in the current
quarter versus 68.3% for the same period last year.
Luxiq(R), Connetics` first dermatology product, produced first quarter
sales of $3.9 million, representing a 72% increase over the same period a year
ago and a 19% increase over the quarter ended December 31, 2000. OLUX(TM),
launched in November 2000, produced sales of $1.7 million, a 44% increase over
the prior quarter. Contract revenues for the first quarter were $0.8 million,
representing primarily a final payment by InterMune Pharmaceuticals, Inc. for
licensing rights to Actimmune. Total revenues for the first quarter were
$8.5 million, compared to total revenue of $13.6 million in the first quarter
of 2000, which included a $5.0 million milestone payment under a former
collaboration agreement.
Total operating costs and expenses for the first quarter were
$13.1 million, compared to $13.5 million in the first quarter of 2000. Net
loss for the first quarter was $4.9 million or ($0.16) per diluted share.
Excluding one-time, non-cash charges, the net loss would have been
$3.5 million. This compares to a net loss of $4.4 million or ($0.16) per
diluted share in the first quarter 2000. As of March 31, 2001, cash and
short-term investments totaled $70.6 million.
"Connetics is rapidly establishing itself as a high growth dermatology
company. We had a record quarter for dermatology product sales and we see the
increasing prescription trend continuing with Luxiq and OLUX," said
Thomas G. Wiggans, President and Chief Executive Officer. "This is an
extremely exciting time period for Connetics. We just closed our acquisition
of Soltec, which provides a broad platform of product technology as well as
valuable revenue. We have nearly doubled the size of our sales force, putting
us in a commanding position to continue our sales growth. The expanded sales
force is fully trained and began calling on dermatologists this week.
Finally, we anticipate starting late-stage clinical trials for new dermatology
product candidates during the second half of 2001. With our assets and
momentum, we are in a strong position to increase shareholder value."

Soltec Acquisition
In March, Connetics entered into a definitive agreement to acquire Soltec
Research Pty Ltd, a division of Australia-based F. H. Faulding & Co Limited
for $32 million Australian. On April 19, 2001, Connetics completed the
acquisition. Connetics` two marketed dermatology products and current
development programs are based on technology developed by Soltec. Soltec is a
profitable company that possesses broad intellectual property and patents on
innovative topical delivery technologies. In addition, Soltec has numerous
license agreements with pharmaceutical companies around the world. The
acquisition of Soltec is expected to provide Connetics with powerful product
innovation and development capabilities, fuel an extensive new product
pipeline, and contribute revenue and profits to Connetics` financial results.

Sales Force Expansion
Also in March, Connetics announced the expansion of its sales force from
41 to 68 persons. The majority of the new representatives joined Connetics
from leading dermatology companies. The sales force expansion gives Connetics
a commercial presence competitive with other leading dermatology companies.
The sales force will focus on driving product revenue growth and will provide
a platform to launch future products.

Addition to Board of Directors
In January, Glenn Oclassen joined the Connetics Board of Directors.
Mr. Oclassen, founder of Oclassen Pharmaceuticals, Inc., is a long-time
executive serving the dermatology community and brings substantial knowledge
of dermatology product development and commercialization to Connetics.
Mr. Oclassen held senior positions at Allergan and later founded the
Neutrogena Dermatologics Division of Neutrogena Corporation. In 1985,
Mr. Oclassen founded Oclassen Pharmaceuticals, Inc., which was regarded as one
of the most successful new dermatology companies ever created, and a premiere
company serving the dermatology community through strong customer service and
successful products. Oclassen Pharmaceuticals was acquired by Watson
Pharmaceuticals in 1997.

Sale of Ridaura
Following the close of the first quarter, Connetics sold its rights to
Ridaura to Prometheus Laboratories Inc., a private company based in San Diego,
for $9.0 million cash plus a royalty on annual sales in excess of $4.0 million
for the next five years. Ridaura is a prescription pharmaceutical product for
the treatment of rheumatoid arthritis.
The Company will hold a conference call to discuss first quarter results
at 4:15 p.m. EDT on Wednesday, May 2, 2001. Interested investors and others
may listen to the call either live by dialing 800-834-5980, access code
18725367 or on a replay basis by dialing 800-633-8284, access code 18725367.
The replay will be available starting May 2, 2001 at 7:00 p.m. EDT, and will
run through 7:00 p.m. EDT on June 2, 2001. The call will also be available
for replay on Connetics` Web site at www.connetics.com through June 2, 2001

..................................................................

Also, ich weiss nicht, was ich davon halten soll. Ich meine, daß es doch gar nicht so schlecht klingt, oder ?

V.Mac

[gony]

Jetzt geht es aber los.
In Amerika + 16%
und hier +25 %
.Jetzt ist noch die Möglichkeit unter zehn Euro einzusteigen.
Ich sage nur nehmt sie war bevor es vorbei ist.

[puhvogel]

Auffällig unauffällig steigen die:
Die Olux-Verkaufzahlen könnten tatsächlich den CNCT Kurs beflügelt haben. Der Verkauf läuft ganz gut an.

[gholzbauer]

Beruhigend ist auch, daß man bei CNCT nicht mehr allzuviel Geld auf Relaxin setzen will. Eine Auslizensierung von Relaxin wäre jetzt noch schön.

[gholzbauer]

8.5$
Es werden wohl gute Zahlen erwartet.


Monday October 15, 7:01 am Eastern Time
Press Release
SOURCE: Connetics Corporation
Connetics Announces Third Quarter Results Conference Call
PALO ALTO, Calif., Oct. 15 /PRNewswire/ -- Connetics Corporation (Nasdaq: CNCT - news), a specialty pharmaceutical company focused on the development and commercialization of innovative, dermatology products, today announced that the Company will host a conference call to discuss third quarter results on Tuesday, October 23, 2001, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time).

To participate in the live call by telephone from the U.S., please call 800-249-3575. To access the call from outside of the U.S., please call 212-676-5022. The conference call will also be broadcast live over the Internet: follow the Investor Relations link at www.connetics.com.

A telephone replay will be available October 23, 2001 beginning at 1:00 p.m. ET (10:00 a.m. PDT) and will run through 3:00 p.m. ET (12:00 p.m. PT) on October 25, 2001. To access the replay from the U.S., please call 800-633-8284. To access the replay from outside of the U.S., please call 858-812-6440. All callers then enter reservation number 19872344. The call will also be available for replay on Connetics` Web site for 90 days.

[Braini]

von mir aus dürfen die weiterlaufen bis nächsten Dienstag....

[gholzbauer]

Upgrade von CIBC auf "Strong buy", Kursziel angeblich von 12$ auf 15$ angehoben lt. Yahoo-Mesage-Board Post #3682.



------------------------------------------------
Re: Conference call summary
by: timoliver1957
Long-Term Sentiment: Strong Buy 10/24/01 07:58 am
Msg: 3670 of 3684

No big surprises in the conference call. Olux is now their #1 drug, more competitive than Luxiq. This quarter will release results from full body psoriasis phase III study (Olux)...they currently are only approved for scalp...this should be big. Still talking with potential partners for relaxin...have several good prospects. Mipharm, their Italian licensee, just picked up Olux and is getting European approval for Olux in all Europe. Will have better forecast of royalty revenues in a quarter or two as some products ramp up. They sound real solid on product sale forecast for 2002 of $40-42 million (50% revenue growth)at a little less than 90% gross margins. Royalties and license fees to be added to that (100% margin). They just received award for #18 fastest growing company in Silicon Valley...but said that they weren`t satisfied with that. Finally, some acquisitions on the horizon probably next year. They want to focus on their pipeline drugs where they have a lot of opportunities. One major drug to go into phase III this quarter to have results second half of next year. Another has been pushed out a couple of quarters to do a more competitive product for acne (longer lasting). They feel that the timing is better for that as well. 18 studies to be released on Phase 4 research at Amer. Derm. association meeting in February. 3 analyst conferences in next few months including one today in New York at 4pm EST. The company is developing quite nicely...institutions will be buying shortly most likely.



Posted as a reply to: Msg 3667 by mss256


--------------

gegenteilige Meinung:

Re: Conference call summary
by: bioprox 10/30/01 12:43 pm
Msg: 3676 of 3684

CNCT put a good face on a dog stock.

Relaxin is DOA. No one is going to touch this until CNCT proves that it hase some legs. That will take time and money.

The stock is fairly priced at its current levels. The products are reformulated standards, they do not offer anything new. As such, they are extremely sensitive to competition from new products that offer any advantage. Getting approval for OLUX whole body is no big deal - people already use it all over. CNCT is becoming a drug delivery company with no proprietary ingredients, at best a 15 multiple.

With a $100M cum deficit, and still losing money this is a bit of a dog. It will need a real product opportunity before it can generate significant market cap.

As far as delaying the acne drug, I consider that a weakness. The company failed to get it right, and now they have to delay. Not a good sign. It means their product is NOT competitive with current products. It may never be competitive, as new products are always being launched in this area.

CNCT mangement lack the skills to turn this around. It is, and will remain, a nice little derm company. It is not, and will not become, a biotech high flier. (at least for the next 5 years)



Posted as a reply to: Msg 3670 by timoliver1957


----------------------------


Mkt. Cap. bei Kurs 8.5 $ beträgt 250 Mio. $.
Umsätze 2001 28 Mio. $, 2002 ca. 40 Mio. $ geplant.
Die Produkte sind nicht sehr innovativ, ein Blockbuster ist bei weitem nicht in Sicht.
Bei gut 10$ werde ich wohl einen Teil meiner CNCT verkaufen.
Was denkt Ihr?

[V.Mac]

#28 von V.Mac 08.11.00 23:13:34 2299225 CONNETICS CORP. DL-,001

also der link ist nicht schlecht bzw. der dargestellte inhalt !

Ich denke, CNCT hat seinen Boden bei rund 6 USD gefunden, auch nicht schlecht, wenn mann bedenkt, daß in der ertsten Verkaufspanik der Kurs bis 4,80 USD gefallen ist.

Langfristig denke ich, das man ruhig wieder auf zweistellige Kurse hoffen kann.

V.Mac

Jetzt, nach knapp einem Jahr, sind tatsächlich wieder zweistellige Kurse erreicht, zumindest in Deutschland.

Für den Langfristanleger ist damit eine 100% Chance auf Sicht von einem Jahr geworden.

Ist doch bei der Gesamtentwicklung der Märkte nicht schlecht.

V.Mac

[gholzbauer]

Bei SCO gibt es einen neuen Research Report:

http://www.scogroup.com/index.php3?category=research&ticker=…

[puhvogel]

@gholz: Heute wär dann wohl dein Verkaufstag.

Connetics Announces Positive Trial Results for OLUX(TM) for the Treatment Of Mild-to-Moderate Body Psoriasis

Results to Serve as Basis for Expanded Product Claims and sNDA Filing

PALO ALTO, Calif., Nov. 5 /PRNewswire/ --
Connetics Corporation (Nasdaq: CNCT) announced today that results from its Phase IV clinical trial of OLUX(TM) (a novel foam formulation of clobetasol propionate, 0.05%) for the treatment of corticosteroid-responsive dermatoses, demonstrated statistically significant improvement over placebo for the treatment of mild-to-moderate body psoriasis. The Company intends to file a supplemental New Drug Application (sNDA) with the FDA by January 2002 to
request clearance to expand the label claims for the drug to include the treatment of non-scalp areas. OLUX is currently on the market as a treatment for steroid responsive scalp dermatoses.
The 279 patient, placebo-controlled, randomized, double-blind, Phase IV study was conducted at 17 clinical centers. Based on a preliminary intent-to-treat analysis of the data, the trial demonstrated that patients
treated with OLUX, administered twice-daily for 14 days, experienced a statistically significant improvement (p <0.0001) over patients in the placebo group. Using the physician global static score, the trial showed that 67% of
patients treated with OLUX had complete or almost complete clearance of disease compared with 21% of patients treated with placebo. The final analysis of the efficacy and safety data is expected to be completed by December 2001.
"We are very enthusiastic about the outcome of this trial," said Thomas G. Wiggans, President and CEO of Connetics. "OLUX, launched only a year ago, has achieved strong initial adoption by dermatologists and patients
for the treatment of scalp dermatoses. The results of this study indicate that OLUX may be effective as a treatment for steroid responsive dermatoses in non-scalp areas. We believe this additional data and the potential label expansion may provide Connetics an opportunity to increase the use of the product."
"The efficacy results of this study are striking," said the Principal Investigator Alice Gottlieb, M.D., Ph.D., W.H. Conzen Chair in Clinical Pharmacology, Professor of Medicine, and Director of the Clinical Research Center at UMDNJ-Robert Wood Johnson Medical School. "OLUX is already provenas an effective and convenient treatment for scalp dermatoses. With these data demonstrating efficacy beyond the scalp, one corticosteroid formulation may be used on both body and scalp, making OLUX a convenient treatment for
patients, doctors and pharmacies."
OLUX is a stabilized foam formulation of clobetasol propionate, 0.05%, a super-high-potency corticosteroid. In 2000, the high and super-high potency steroid category generated $457 million in sales in the U.S. OLUX foam
liquefies when applied to the skin and is designed to deliver the active drug to the disease site. In addition, the foam formulation is designed to be easier-to-apply, less messy and cosmetically more acceptable than currently
marketed dermatological solutions, creams, ointments and gels. In market research sponsored by Connetics, 80% of patients said that they preferred the foam over other topical delivery vehicles.

[gholzbauer]

Ich glaube, SCO hat mich umgestimmt

[puhvogel]

Ich kenne mich mit Schuppenflechte herzlich wenig aus (für meinen Geschmack zu viel Konkurrenz im Anlauf), aber die Ergebnisse sehen optisch bärenstark aus!

[gholzbauer]

p <0.0001

[puhvogel]

Tjaaaa, de Kursreaktion ist ja wirklich enttäuschend.
p<0.0001 steht eigentlich für
the trial showed that 67% of patients treated with OLUX had complete or almost complete clearance of disease compared with 21% of patients treated with placebo.

Das klingt eigentlich ganz gut. Hat jemand schon diese Daten mit Konkurrenzprodukten verglichen?

[Braini]

buff... was war das denn ?? 12% + heut , verdoppelt in den letzten 5 monaten... jetzt kann man mal langsam dran denken ein paar gewinne mitzunehmen denke ich .... .

[Braini]

Hat irgendjemand ne meldung zu connetics gefunden ? oder sind die meldungslos auf ein neues high gesprungen ?

[puhvogel]

Die eigentliche Meldung zum Kurssprung wäre die von #45 gewesen. Oder findest Du die Aussage von #50 nicht gut?

[Braini]

heimlich still und leise über 10 dollar gestern. unddas ganze ohne aufsehen. sieht so aus als ob das gap bei 15 angepeilt wird. gut so .

[Braini]

keiner hier ? trotz so viel freude mit dieser Aktie ? naja, in Deustchland wenig bis gfar kein handel. schad drum

[newdrogo]

Hallo Braini,

keien sorge, sind schon noch welche da, die diese perle still und leise genießen.

Und handel findet übrigens auch statt...

Gruß
newdrogo

[puhvogel]

Da war ja heute ein wunderschönes Intraday-Reversal. Das lässt ja auf mehr hoffen
Ab heute läuft bei mir ein trailing stop-loss mit, denn ab nun sind die Gewinne steuerfrei.

[outperformancer]

Wundere mich warum Connetics so wenig Aufmerksamkeit hat.
Sind es denn so wenige hier am Board, die diesen Wert im Depot haben. Bin knapp 100 % im Plus. Soll man Connetics jetzt verkaufen, oder steigen die noch gegen 15 $. Was meint ihr.Die sind relativ stabil auch wenn Nasdaq fällt.

[Bruder_Jeremias]

http://communities.msn.de/um3nh65c7p4/heietipps.msnw?action=…

[puhvogel]

Wie gesagt, habe ich ein gewisses steuerliches Interesse, die Aktie zu verkaufen, will aber die Gewinne laufen lassen. So rufe ich Bigchart auf und lasse mir einen 38 Tage Schnitt zeichen, den ich dann als gedanklichen Stop-Loss weiterlaufen lasse. Auch bei einem plötzlichen sehr starken Anstieg würde ich auch verkaufen.

Das ist alles nicht ausgetüftelt, aber in der Vergangenheit recht wirksam gewesen.
Bei den bei Biotechs häufigen 50 % drops aufgrund schlchter Nachrichten wie auch im Oktober 2000 hilft das natürlich nicht die Bohne.
Die Aktie hält sich auch serh gut und hat aufgrund der fundamentalen Lage gute Chancen weiter zu steigen, da isch das Olux offenbar ganz gut verkauft. Mir gefiel vor allen Dingen, dass der CEO in seinen Präsentationen immmer stark die Verkaufsseite betonte und nicht nur forschungsverliebt war! Da besteht offenbar auch ein Zusammenhang.

[Braini]

die aktie wird leider in deutschland ganz wenig gehandlet . heut bahnt sich ein neues 52 wochen hoch an. zumindest mal zwischenzeitlich. ich mag nicht verkaufen obwohl es ja sinnig wäre bei 100% gewinn...

[gholzbauer]

Break des alten (kurzfr.) Hochs!
In den jetzt folgenden Anstieg werde ich zumindest einen Teil verkaufen; werde evtl. 1:1 in HAL tauschen, oder 1:2 in CVAS.

[Braini]

hammer oder ?? 13.95 , gibt s nen grund ??

[gholzbauer]

Momentum players, IMO.
Morgen schmeiß ich die restlichen CNCT raus, glaub ich.
Für mich ist dieser Hype nicht nachvollziehbar.
Trotzdem "extrem O.K."

[gholzbauer]

O.K., hab den Rest zu 13.65$ verkauft.

Gestern schon die ersten CVAS gekauft, heute sind wohl GZMO dran ...


"If nothing`s ventured nothing`s gained
so I must seize the day."
VNV Nation - Standing (still)

[puhvogel]

Vielleicht war das ein Fehler. Ich als Kontraindikator habe nämlich die auch nach dem 17% Anstieg verscherbelt, wie in #60 angekündigt. Für mich ist CNCT neben der Käsekommerzbank die positive Überraschung im Depot im Jahr 2001, nicht aber Bestperformer: Das sind meine 42 Interneuron-Aktien, die mir der Makler nicht abnehemen wollte. .
Die negativste Überraschung war ohne jede Frage AVXT.

[gholzbauer]

Dann war mein Ausstieg wohl doch etwas zu früh ...
Die potenziellen Technologie-Lizenzeinnahmen habe ich unterschätzt, wie`s scheint.




Wednesday January 2, 4:15 pm Eastern Time
Press Release
SOURCE: Connetics Corporation
Connetics Licenses Foam Delivery Technology to Pharmacia for Use With Rogaine(R)
PALO ALTO, Calif., Jan. 2 /PRNewswire/ -- Connetics Corporation (Nasdaq: CNCT - news) announced today the signing of a licensing agreement granting Pharmacia Corporation (NYSE: PHA - news) exclusive global rights, excluding Japan, to Connetics` proprietary foam drug-delivery technology for use with Pharmacia`s Rogaine® hair loss treatment.

Under the agreement, Pharmacia will pay Connetics an undisclosed initial licensing fee, milestone payments and a royalty on product sales. Pharmacia will be responsible for most product development activities and costs.

``This is the second major partnership for a leading global OTC brand we have signed,`` said Thomas G. Wiggans, Connetics` President and Chief Executive Officer. ``This underscores the opportunity to innovate new brands and to strengthen existing brands using our delivery technologies. The potential royalties from these partnerships will be important additions to our revenue and earnings over the coming years.``

Mr. Wiggans added, ``Patient compliance is a significant challenge for hair loss treatments, and surveys among dermatologists and consumers have repeatedly demonstrated a strong preference for a foam delivery vehicle. We are delighted to enter into this agreement with Pharmacia which markets the leading topical brand for treating hair loss.``

Pharmacia Consumer Healthcare, a unit of Pharmacia Corporation, is a global leader in the field of hair loss treatments. More than 40 clinical studies have shown Rogaine topical solution to be safe and effective in treating hair loss in both men and women.

[Braini]

du hast doch zu 13.65 verkauft . würdest jederzeit wieder reinkommen zu dem preis denk ich . nachbörslich knapp über 13. ich denk dass nach dem nächsten kursschub erstmal ne verkaufswelle einsetzt.

[outperformancer]

Habt ihr eure cnct schon alle verkauft? Ich glaube cnct wird noch weiter steigen.

[FLOTSAM_AND_JETSAM_US]

FDA Files Connetics Application to Expand Label Claims of OLUX(R)
OLUX Anticipated to Treat Mild-to-Moderate Body Psoriasis in Non-Scalp Areas
PALO ALTO, Calif., March 4 /PRNewswire-FirstCall/ -- Connetics Corporation (Nasdaq: CNCT - news), a specialty pharmaceutical company focused exclusively on the development and commercialization of dermatology products, has received confirmation that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company`s supplemental New Drug Application (sNDA) to expand the label claims for OLUX to include the treatment of non-scalp areas and is under review. The submission was made on December 26, 2001. OLUX is currently on the market as a treatment for steroid responsive scalp dermatoses.

Thomas G. Wiggans, Connetics President and Chief Executive Officer, commented, ``The filing of our sNDA for OLUX is good news for Connetics. OLUX is already proven as an effective and convenient treatment for scalp dermatoses. Approval of the expanded OLUX label could provide us with an opportunity to pursue additional significant revenue potential -- the market for non-scalp areas is estimated to be in excess of $600 million.``

Mr. Wiggans added, ``We will continue our strong commitment to developing technically superior products that will ultimately benefit doctors, pharmacies and patients. As part of our ongoing product development program, 18 abstracts about our products were presented at the Annual Meeting of the American Academy of Dermatology held in February 2002.``

In November 2001, Connetics completed a 279-patient, placebo-controlled, randomized, double-blind, Phase IV study at 17 clinical centers. Patients, who were administered either OLUX Foam or placebo twice-daily for 14 days, were evaluated using the Physician`s Static Global Assessment score as the primary endpoint; patient`s global assessment and erythema, scaling, plaque thickness, and pruritus changes from baseline were used as secondary endpoints.

Study investigator Ken Washenik, M.D., Ph.D., presented findings of the study in January 2002 at the 26th Annual Hawaii Dermatology Seminar, in which patients with mild-to-moderate plaque-type psoriasis of non-scalp regions treated with OLUX Foam experienced a statistically significant improvement in clearance of disease (p < 0.0001) over patients in the placebo group.

[Braini]

warum reagiert der kurs so beschissen negativ ?????

[puhvogel]

Weil es eine gute Nachricht ist.

[gholzbauer]

damit ich billig zurückkaufen kann - aber nicht heute, dünkt mich ...

[puhvogel]

In der Tat. Es riecht danach als würden hier alte Positionen bereingt, und das könnte seine Zeit benötigen.

[gholzbauer]

Monday March 4, 1:06 pm Eastern Time
Connetics says FDA accepts application; stock falls
NEW YORK, March 4 (Reuters) - Drug developer Connetics Corp. (NasdaqNM:CNCT - news) said on Monday U.S. regulators accepted its application to market its scalp psoriasis ointment for wider usage, but analysts were unsure why the company`s stock has dropped.


Connetics said the U.S. Food and Drug Administration accepted its filing to sell Olux for the skin disorder psoriasis for use on parts of the body other than the scalp. The topical treatment is currently indicated only for use on the scalp.

But shares of the Palo Alto, California-based company fell 16.2 percent, or $1.62, to $8.38 in afternoon Nasdaq trading.

``There`s a disconnect, because the news was positive, although it was widely expected,`` said Steven Gerber of CIBC World Markets.

He said he did not know why the stock was down on the day the company announced essentially a ``non-event.`` Connetics filed the application on Dec. 26, 2001.

``We`re suspicious that there may just be a holder out there who may need to liquidate some stocks for other reasons,`` Gerber said.

``There were some venture capitalists in this stock who distributed their shares to the limited partner investors at the beginning of the year. Maybe some of those folks are liquidating their positions,`` he added.

Robert Wasserman an analyst at Sterling Financial said his firm has a neutral rating on the stock but was considering upgrading the rating after Monday`s drop-off.

He said he could not account for the stock decline, but noted that ``it`s been a tough market for all the dermatology companies.``

He added that some investors may be using Monday`s news as an excuse to sell-off the stock.

Both Wasserman and Gerber said they expected the FDA to approve the wider use of Olux.

Gerber said the market for non-scalp psoriasis cremes and ointments is about five times larger than the scalp market.

The company posted a loss of $302,000, or 1 cent per share, on product revenues of $9.0 million for the fourth quarter.

[puhvogel]

Das ist das für mich am meisten unterschätzte Ereignis.
So weit ich mich erinnere , werden etwa 10 % aller NDAs nach einem Monat an den Antragsteller wieder zurückgeschickt, und fast nie gibt es eine signifikante Aufwärtsbewegung. Eine typsiche no-win-no win Situation.
Der letzte war eine unbekannte Firma namens Imclone. Wenn Institutionelle diesen Termin zum Verkauf nutzen,dann ist das beinahe eine Unverschämheit. Es ist natürlich aber deren Sache, wann wo und zu welchem Kurs sie verkaufen.

[Braini]

bei der katstrophalen nasdaq heut hält sich connetics mehr als prächtig . kommen da bald zahlen ? wie kann das sein ? 15% in zwe tagen ohne news ??

[Bruder_Jeremias]

Sollten 13$ geknackt werden, geht die Party los

[[KERN]Codex]

wir waren druff aber leider haben wir die 13€ noch net geknackt - naja ich kann warten =)

[Braini]

tja , geknackt wären se jetzt , aber das hatten wir schon zweimal... mal sehen obs hält.... schön wärs...

[erkilein]

bei 14 $ würd ich gewinne mitnehmen und abwarten, sollte ein neuer top-kurs um die 15 erreicht werden, kann man wieder reingehen, mir scheint aber, eine Anbahnung eines doppeltops steht bevor.

[[KERN]Codex]

so bin seit 12,5$ dabei

[gholzbauer]

Warum ist hier so wenig los?

Seit Monaten warte ich auf günstige Kurse bei CNCT.
Zwischen 5 und 6$ (SL 4,5-5$) wäre das Chance/Risiko-Verhältnis wieder OK für mich (Mkt Cap dann 150-180 Mio bei Umsatzprojektion von 65 Mio$; allerdings z.Z. nur noch gut 1$ Cash/share - ein weiteres Hinausschieben des break-even wäre gar nicht schön).
Wenn ich den Chart so anschaue, könnte es bald klappen mit den 6$.
Bei verbesserter Stimmung im neuen Jahr und/oder weiter guten Absatzzahlen von CNCT sollten irgendwann in 2003 wieder deutlich über 10$ drin sein.

[V.Mac]

Da ich nach wie vor im E-Mail Verteiler von Connetics eingeschrieben bin, werde ich auch ab und zu an die Firma erinnert.

Da hab ich mir gedacht, wird Zeit, mal wieder etwas Senf abzulassen.

Ne, im Ernst: Das nenne ich ne gute Erholung von dem Crash im Otober 2000.

Da konnte mann locker für unter 5 € (wieder) einsteigen und hätte bis heute, also knapp 2 1/2 Jahre später, seinen Einsatz verdreifacht. Mehr gibts auf dem Sparbuch auch nicht *-

Schade, schade.....

V.Mac